Skip to content

Main Navigation

TandemAI
  • Services
    • In Silico Drug Discovery
    • Fully Integrated Wet Labs
  • Technology
    • Physics-Based Molecular Simulation
    • Artificial Intelligence
    • Supercomputing Infrastructure
  • About
    • Leadership
    • Partnering With Us
  • Careers
    • Culture
    • Open Positions
  • News and Events
    • Press Releases
    • Media Coverage
    • Events
  • Contact
Home » News and Events » Press Releases

Archives

  • Jan. 17, 2023

    TandemAI Announces Appointment of Alessandro Monge, Ph.D., as Chief Business Officer

  • Aug. 25, 2022

    TandemAI Announces Appointment of Steve Swann, Ph.D., as Chief Scientific Officer

  • Jan. 18, 2022

    TandemAI Announces Expansion of Senior Leadership Team

  • Dec. 21, 2021

    TandemAI Announces $25 million Seed & Pre-series A Financing led by OrbiMed and Chengwei Capital

  • Services
    • In Silico Drug Discovery
    • Fully Integrated Wet Labs
  • Technology
    • Physics-Based Molecular Simulation
    • Artificial Intelligence
    • Supercomputing Infrastructure
  • About
    • Leadership
    • Partnering With Us
  • Careers
    • Culture
    • Open Positions
  • News and Events
    • Press Releases
    • Media Coverage
    • Events
  • Contact

Discover With Us

Our scientists and technological experts collaborate with the global scientific community to democratize the drug development process and help our clients dramatically improve the success rate of pre-clinical drug candidates. Reach out to discover what we can do together.

Reach Out
News and Events Media Coverage
TandemAI
  • Services
  • Technology
  • About
  • Careers
  • News and Events
  • Contact
Follow:
© 2023 TandemAI 苏州腾迈医药科技有限公司. All Rights Reserved.Privacy PolicyTerms of Use 苏公网安备 32050602011676号苏ICP备2022028953号